Analysts Set Dolby Laboratories (NYSE:DLB) Target Price at $92.00

Dolby Laboratories (NYSE:DLB) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $92.00.

A number of analysts recently issued reports on the company. Rosenblatt Securities decreased their price objective on Dolby Laboratories from $95.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Barrington Research lowered their price target on shares of Dolby Laboratories from $100.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, November 19th. Weiss Ratings restated a “hold (c-)” rating on shares of Dolby Laboratories in a research report on Monday. Robert W. Baird started coverage on shares of Dolby Laboratories in a report on Friday, September 5th. They set a “neutral” rating and a $74.00 target price on the stock. Finally, Baird R W upgraded shares of Dolby Laboratories to a “hold” rating in a research note on Friday, September 5th.

Dolby Laboratories Stock Performance

Shares of DLB stock opened at $67.09 on Monday. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of 25.51 and a beta of 0.89. The firm’s 50-day simple moving average is $66.88 and its two-hundred day simple moving average is $71.25. Dolby Laboratories has a 52 week low of $64.02 and a 52 week high of $89.66.

Dolby Laboratories (NYSE:DLB) last posted its quarterly earnings results on Tuesday, November 18th. The electronics maker reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.29. Dolby Laboratories had a return on equity of 11.99% and a net margin of 18.90%.The company had revenue of $307.02 million during the quarter, compared to the consensus estimate of $305.76 million. During the same quarter in the prior year, the company earned $0.61 EPS. The firm’s quarterly revenue was up .7% compared to the same quarter last year. Dolby Laboratories has set its FY 2026 guidance at 4.190-4.340 EPS and its Q1 2026 guidance at 0.790-0.940 EPS. Analysts forecast that Dolby Laboratories will post 2.94 earnings per share for the current year.

Dolby Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Tuesday, December 2nd were paid a dividend of $0.36 per share. This is a positive change from Dolby Laboratories’s previous quarterly dividend of $0.33. This represents a $1.44 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, December 2nd. Dolby Laboratories’s dividend payout ratio is 54.75%.

Insiders Place Their Bets

In other Dolby Laboratories news, CEO Kevin J. Yeaman sold 36,699 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $66.91, for a total value of $2,455,530.09. Following the transaction, the chief executive officer directly owned 114,725 shares in the company, valued at $7,676,249.75. This represents a 24.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John D. Couling sold 7,273 shares of Dolby Laboratories stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $68.75, for a total value of $500,018.75. Following the sale, the senior vice president owned 108,065 shares of the company’s stock, valued at approximately $7,429,468.75. This trade represents a 6.31% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 162,120 shares of company stock valued at $10,906,559 in the last ninety days. Corporate insiders own 38.39% of the company’s stock.

Institutional Investors Weigh In On Dolby Laboratories

A number of hedge funds have recently made changes to their positions in DLB. MAI Capital Management grew its holdings in shares of Dolby Laboratories by 87.1% during the 1st quarter. MAI Capital Management now owns 348 shares of the electronics maker’s stock valued at $28,000 after purchasing an additional 162 shares during the last quarter. First Horizon Corp bought a new stake in Dolby Laboratories in the third quarter worth $25,000. Hantz Financial Services Inc. boosted its position in Dolby Laboratories by 166.7% during the third quarter. Hantz Financial Services Inc. now owns 352 shares of the electronics maker’s stock valued at $25,000 after buying an additional 220 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Dolby Laboratories in the first quarter valued at approximately $29,000. Finally, Allworth Financial LP raised its holdings in Dolby Laboratories by 590.4% during the 2nd quarter. Allworth Financial LP now owns 504 shares of the electronics maker’s stock valued at $37,000 after buying an additional 431 shares during the last quarter. 58.56% of the stock is currently owned by institutional investors.

Dolby Laboratories Company Profile

Dolby Laboratories, Inc creates audio and imaging technologies that transform entertainment at the cinema, DTV transmissions and devices, mobile devices, OTT video and music services, home entertainment devices, and automobiles. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, a digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and various media devices.